Latest Market Entry News

Page 3 of 56
ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.
Ada Torres
Ada Torres
28 Aug 2026
LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.
Ada Torres
Ada Torres
28 Aug 2026
Swift TV Ltd advanced its commercial rollout with 7,190 devices sold and secured key technology certifications in FY26, while navigating a 22% revenue decline due to legacy contract wind-downs. The company delivered positive EBITDA and raised $2.3 million to fund growth initiatives.
Sophie Babbage
Sophie Babbage
28 Aug 2026
Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.
Ada Torres
Ada Torres
27 Aug 2026
Me Today Limited delivered a 36% revenue surge to $7.96 million in FY26, cutting its EBITDA loss by 43% and locking in $1.59 million of new capital from major shareholders ahead of October warrant exercises.
Victor Sage
Victor Sage
27 Aug 2026
Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.
Victor Sage
Victor Sage
26 Aug 2026
Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.
Ada Torres
Ada Torres
26 Aug 2026
NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.
Ada Torres
Ada Torres
25 Aug 2026
Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.
Ada Torres
Ada Torres
25 Aug 2026
Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.
Ada Torres
Ada Torres
25 Aug 2026
Janison Education Group posted a 3% revenue rise to $48.1 million in FY26, underpinned by international contract expansion and AI innovation, despite margin pressure from onboarding costs.
Victor Sage
Victor Sage
25 Aug 2026
Acusensus posted a 45% jump in FY26 revenue to $86.2 million, driven by major contract wins in New Zealand and the US, alongside robust domestic expansions. Despite a widened net loss due to a $16 million litigation settlement, adjusted EBITDA climbed 49%, reflecting operational momentum and strategic investments.
Sophie Babbage
Sophie Babbage
25 Aug 2026

Browse the archive

Full archive